eighty-five menopausal women ( mean age 56 years ) with endometrial hyperplasia without ( 65 patients , group 1 ) and with cytologic atypia ( 20 patients , group 2 ) were followed up prospectively from 2 to 12 years ( mean 7 years ) to shed insight into their respective response to oral medroxyprogesterone acetate therapy .
C0014173
endometrial hyperplasia
C0065864
medroxyprogesterone acetate